Nestlé: to acquire US food allergy firm Aimmune
(CercleFinance.com) - Nestlé said on Monday that it has reached an agreement to acquire Aimmune Therapeutics, the Swiss food giant's latest US investment to step up its focus on medical nutrition.
The Vevey-based Nestlé said it will begin a cash tender offer to acquire all of Aimmune's outstanding shares, a US-based biopharmaceutical firm commercializing treatments for food allergies, based on a total enterprise value of 2.6 billion dollars.
Aimmune's Palforzia helps reduce the frequency and severity of allergic reaction to peanuts in children.
Up to 240 million people worldwide suffer with food allergies, with peanut allergy being the most common, Nestlé said.
The acquisition is expected to be accretive to Nestlé's organic growth in 2021 and accretive to cash earnings by 2022/23.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Vevey-based Nestlé said it will begin a cash tender offer to acquire all of Aimmune's outstanding shares, a US-based biopharmaceutical firm commercializing treatments for food allergies, based on a total enterprise value of 2.6 billion dollars.
Aimmune's Palforzia helps reduce the frequency and severity of allergic reaction to peanuts in children.
Up to 240 million people worldwide suffer with food allergies, with peanut allergy being the most common, Nestlé said.
The acquisition is expected to be accretive to Nestlé's organic growth in 2021 and accretive to cash earnings by 2022/23.
Copyright (c) 2020 CercleFinance.com. All rights reserved.